Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Articles by Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCSeptember 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCSeptember 23rd 2020
Practical Management of Early Stage HER2+ Breast CancerSeptember 23rd 2020
HER2-targeted Therapy: Routes of AdministrationSeptember 23rd 2020
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5